Brokerages Anticipate Jazz Pharmaceuticals plc – (JAZZ) Will Post Quarterly Sales of $432.77 Million

Wall Street brokerages forecast that Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) will report sales of $432.77 million for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $419.09 million and the highest estimate coming in at $448.38 million. Jazz Pharmaceuticals reported sales of $376.05 million in the same quarter last year, which would suggest a positive year over year growth rate of 15.1%. The company is expected to announce its next quarterly earnings results on Tuesday, May 8th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full-year sales of $432.77 million for the current fiscal year, with estimates ranging from $1.87 billion to $1.90 billion. For the next fiscal year, analysts expect that the firm will report sales of $2.14 billion per share, with estimates ranging from $2.06 billion to $2.21 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Jazz Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.73 by ($0.15). The firm had revenue of $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a net margin of 30.14% and a return on equity of 22.63%.

JAZZ has been the topic of a number of recent analyst reports. Leerink Swann initiated coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, January 2nd. They issued an “outperform” rating and a $180.00 price objective on the stock. Zacks Investment Research raised shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 12th. Cantor Fitzgerald reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Sunday, December 10th. BidaskClub raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 13th. Finally, Bank of America lifted their price objective on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, February 20th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seventeen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $181.04.

In related news, CFO Matthew P. Young sold 700 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $151.22, for a total value of $105,854.00. Following the sale, the chief financial officer now owns 39,165 shares of the company’s stock, valued at $5,922,531.30. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Matthew P. Young sold 3,135 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $146.85, for a total transaction of $460,374.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,758 shares of company stock worth $1,881,171. Insiders own 4.30% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. US Bancorp DE grew its stake in shares of Jazz Pharmaceuticals by 49.5% in the fourth quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock worth $147,000 after purchasing an additional 360 shares during the last quarter. We Are One Seven LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $157,000. Invictus RG bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $206,000. Advisor Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 62.4% in the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock worth $210,000 after purchasing an additional 550 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Jazz Pharmaceuticals by 795.4% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,746 shares of the specialty pharmaceutical company’s stock worth $255,000 after purchasing an additional 1,551 shares during the last quarter. 91.20% of the stock is currently owned by institutional investors.

JAZZ stock opened at $147.98 on Friday. The stock has a market cap of $9,194.17, a P/E ratio of 18.61, a P/E/G ratio of 0.80 and a beta of 0.97. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.29 and a quick ratio of 3.15. Jazz Pharmaceuticals has a one year low of $128.58 and a one year high of $163.75.

ILLEGAL ACTIVITY WARNING: “Brokerages Anticipate Jazz Pharmaceuticals plc – (JAZZ) Will Post Quarterly Sales of $432.77 Million” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3294874/brokerages-anticipate-jazz-pharmaceuticals-plc-jazz-will-post-quarterly-sales-of-432-77-million.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

PRCoin  Market Capitalization Hits $18,688.00
PRCoin Market Capitalization Hits $18,688.00
Creatio  Trading 7.1% Higher  This Week
Creatio Trading 7.1% Higher This Week
Cherokee  versus J.Jill  Financial Analysis
Cherokee versus J.Jill Financial Analysis
Head to Head Comparison: Allegheny Technologies  & Synalloy
Head to Head Comparison: Allegheny Technologies & Synalloy
$49.78 Million in Sales Expected for FranklinCovey  This Quarter
$49.78 Million in Sales Expected for FranklinCovey This Quarter
Analyzing Gladstone Commercial  & HFF
Analyzing Gladstone Commercial & HFF


© 2006-2018 Ticker Report. Google+.